Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →Filing growth compares 2021 (436 records) with 2024 (231) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 5,157 records in scope (CR5), not by the ranked leaders only.
Lentiviral vector manufacturing patents cluster around three practical problems: getting a packaging or producer cell line to hold a stable, high-titer output; choosing an envelope pseudotype that sets tropism without compromising particle stability; and controlling process variables — shear sensitivity, residual plasmid, transduction unit consistency — well enough to satisfy regulators. The search set spans 5,157 records filed or published between 2015 and mid-2026, drawing on classes for microorganism engineering, medicinal preparations and peptide chemistry rather than a single narrow art class.
Filing activity rose through the late 2010s, peaked in 2021, and has since declined through the last complete year on record. Publication lags filing by roughly 18 months, so 2025 and 2026 figures will keep filling in and should not yet be read as a trend reversal.
Pick a task. Every answer cites the patents behind it.
The filing curve and the IPC mix below are drawn directly from the 5,157 records in scope, using the same denominators throughout — no class share is computed against anything other than the full record count.
Filings ran from 261 in 2017 to a peak of 436 in 2021, then declined to 231 by 2024 — a 47% drop over that three-year span. Years after 2024 are still incomplete because of publication lag and should not be read against this figure.
C12N (microorganisms and genetic engineering) appears on 79.7% of records and A61K (medicinal preparations) on 64.3%, confirming that most filings claim either the vector construct itself or its therapeutic formulation. C07K (peptides and proteins, 40.6%) and A61P (therapeutic activity, 25.9%) trail well behind. Process-adjacent classes — C12Q (5.7%), C12P (4.0%), C07H (4.1%) and C12R (3.1%) — are claimed far less often, which is where manufacturing-process detail tends to sit outside the core construct claims.
Shares are the percentage of the 5,157 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about lentiviral vector manufacturing and every answer comes back with the patent numbers behind it.
Try EurekaThe present disclosure provides a method of generating a stable producer cell line. The generation of stable producer cell lines, such as those provided in accordance with the present invention, increases the reproducibility and ease of creating high titer lentiviral stocks while easing biosafety concerns, and the variation in expressed envelope proteins defines the tropism of the generated virus. The present disclosure also provides for a novel lentiviral transfer vector plasmid.Filed by CSL Behring Gene Therapy and granted 2022-04-12, this filing sits squarely in the stable-producer-cell-line branch that the assignee ranking shows is contested rather than owned by a single leader.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US4861719A | DNA constructs for retrovirus packaging cell lines | 1,200 |
| 2 | US5814482A | Eukaryotic layered vector initiation systems | 995 |
| 3 | WO1993025698A1 | Vector particles resistant to inactivation by human serum | 929 |
| 4 | WO1995007994A2 | Recombinant alphavirus vectors | 776 |
| 5 | WO1996017072A2 | Recombinant alphavirus vectors | 746 |
| 6 | WO1997009441A2 | Improved AAV vectors for gene therapy | 555 |
| 7 | US5843723A | Alphavirus vector constructs | 511 |
| 8 | US5789245A | Alphavirus structural protein expression cassettes | 495 |
| 9 | US6015686A | Eukaryotic layered vector initiation systems | 471 |
| 10 | WO1998017815A1 | Retroviral vectors | 353 |
Citation counts favour older filings inside any searched corpus; treat them as a signal of influence on downstream art, not as a ranking of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Three patterns stand out once the raw counts are read against each other: a real post-2021 pullback, a technology mix skewed toward construct and formulation claims, and a leadership picture that is concentrated at the very top but long-tailed everywhere else.
Filings fell from 436 in 2021 to 231 in 2024, the last year the dataset treats as complete. That three-year decline predates the publication-lag window, so it reflects an actual reduction in new filing activity rather than records still working through the pipeline.
The top 5 ranked assignees combine for 18.4% of all 5,157 records and the top 10 for 29.8%. That leaves more than two-thirds of the corpus spread across the remaining ranked entrants and unranked filers, a structure that favours a freedom-to-operate search over assuming one player owns the space.
C12N and A61K together sit on the large majority of records, showing that most applicants claim the vector construct or its formulation rather than downstream manufacturing steps. Classes tied to enzymatic and fermentation process control — C12Q, C12P, C07H, C12R — each sit under 6% of records.
The United States receives the largest single share of filings tracked (1,137), followed by the EPO (816) and WIPO/PCT (787), with Australia, Israel and Canada some way behind. That order is typical of a biologics field where applicants file nationally in the largest markets while keeping a PCT option open.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to lentiviral vector manufacturing, with the prior art for and against each one.
The assignee ranking covers 100 companies and institutions counted by patent family. Leadership is concentrated at the very top but thins quickly, and recent-year momentum data suggests most of the historic leaders have gone quiet in the most recent tracked year — consistent with the broader post-2021 pullback rather than any single company's retreat.
The leading assignee holds 217 records against 161 for the fifth-placed entrant and 105 for tenth — a steep but not runaway drop-off, indicating an active but not monopolised leadership tier.
The strongest co-assignee pairing in the dataset spans 130 shared records, with two further pairings at 64 and 46. All three of the strongest pairs involve the same French research institute, pointing to an academic-industry cluster rather than isolated joint ventures.
Recent-year momentum for several previously active assignees — universities, research institutes and a gene-therapy specialist among them — shows year-on-year declines approaching or at -100%, echoing the field-wide drop from the 2021 peak rather than signalling any single firm's exit.
| Assignee | Recent year | YoY |
|---|---|---|
| Novartis AG | 2 | +100% |
| The Regents of the University of California | 1 | -88% |
| City of Hope | 0 | -100% |
| Flagship Pioneering Innovations VI, LLC | 0 | -100% |
| Institut Pasteur | 0 | -100% |
| Genzyme Corp | 0 | -100% |
| Theravectys | 0 | -100% |
| TCR2 Therapeutics Inc | 0 | — |
The dataset points to a field with occupied core claims and thinner process-side coverage. Two follow-on steps make that actionable.
With 29.8% of records held by ten entrants, a targeted FTO search against just those filers covers a meaningful share of the risk before widening to the full ranked list.
Explore assignee claims in EurekaBecause C12Q, C12P, C07H and C12R each sit under 6% of records, a claim drafted tightly around process control is less likely to collide with the dense C12N and A61K filings.
Map white space in EurekaThe dataset's assignee ranking shows one clear leader with 217 records, followed by a fifth-placed entrant at 161 and a tenth-placed entrant at 105. The gap from first to tenth is real but not extreme, meaning no single organisation controls the field outright. The top 10 combined hold 29.8% of all 5,157 records in scope, leaving the majority spread across a long tail of smaller filers.
No — filings peaked in 2021 at 436 and had fallen to 231 by 2024, a 47% decline over that span, and 2024 is the most recent year the dataset treats as complete. Figures for 2025 and 2026 are still filling in because publication typically lags filing by around 18 months, so they should not yet be read as confirming or reversing that trend. The honest read is a real pullback from a 2021 peak, not a field in early growth.
Vector construction and genetic engineering (IPC class C12N) appear on 79.7% of the 5,157 records in scope, and medicinal preparation claims (A61K) appear on 64.3%. Peptide and protein chemistry (C07K) and therapeutic activity claims (A61P) follow at 40.6% and 25.9% respectively. Process-control classes tied to enzymatic testing, fermentation and microorganism indexing each sit under 6%, which is where manufacturing-process detail is comparatively under-claimed relative to the core construct and formulation space.
US11299752B2, assigned to CSL Behring Gene Therapy and granted in April 2022, claims a method of generating a stable producer cell line for lentiviral vectors along with a lentiviral transfer vector plasmid. Its stated purpose is improving the reproducibility and titer of stable producer lines while addressing biosafety and envelope-protein variation that affects viral tropism. Anyone building a stable producer cell line for lentiviral manufacturing should review its claim scope directly rather than relying on the abstract, since the assignee ranking shows this branch is actively contested rather than owned by one party.
The clearest gaps sit in process-adjacent IPC classes — C12Q, C12P, C07H and C12R — each claimed on under 6% of the 5,157 records in scope, against C12N's 79.7% and A61K's 64.3%. That imbalance suggests manufacturing-process detail such as shear control in closed bioreactor systems, residual plasmid clearance, and producer-cell genomic stability testing is comparatively under-claimed relative to the construct and formulation space. A narrowly drafted process claim in one of these areas is more likely to clear existing prior art than a further construct-level filing.
Go past this page: query the whole lentiviral vector manufacturing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page